The use of the combined drug «Urolife-Next» for recurrent lower urinary tract infections: clinical and microbiological aspects

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. Improving the efficiency of treatment and prevention of recurrent lower urinary tract infection (LUTI) is an important problem in modern urology. A significant role is given to the non-antibiotic measures.

Aim. To evaluate the clinical and microbiological efficiency of the drug Urolife-Next in patients with recurrent UTI.

Materials and methods. A total of 70 women with recurrent UTI aged 18 to 55 years (mean 35.1±10.1) and symptoms of cystitis were included in the study. After antibacterial therapy, all patients were divided into 3 groups. In the group 1 (n=24), patients took Urolife-Next 1 capsule 3 times a day for 90 days, in the group 2 (n=23) Э Urolife-Next in the same dose, but for a period of 30 days, while patients of group 3 (n=23) did not receive any treatment. The total follow-up period was 90 days. Frequency and severity of symptoms of recurrent UTI were assessed. The microbiological part of the study included evaluation of the presence and severity of anti-adhesive, anti-biofilm and direct antibacterial effects of the Urolife-Next against uropathogens isolated from urine of patients with exacerbation of UTI.

Results. In group 1, in which patients took Urolife-Next throughout the study, the lowest frequency of relapses was seen. During the 90-day follow-up, recurrences of UTI occurred in only 3 (12.5%) patients in group 1, compared to 18 (78.3%) in group 3. In addition, in the group 1 there was a significantly lower severity of symptoms during exacerbation of cystitis compared to the initial episode, as well as to 3. Urolife-Next showed antibacterial activity against 29 (41.4%) of 70 strains of uropathogens. The minimum inhibitory concentration of Urolife-Next against gram-negative microorganisms was on average 2 times higher than for gram-positive pathogens. A pronounced anti-adhesive activity of Urolife-Next in vitro was also revealed. The maximum anti-adhesive effect was observed 2 hours after the start of the study. By this time, the adhesion index for cultures in the presence of Urolife-Next was 2.3 times lower than the control values for E. coli, 2.5 times for Kl. pneumoniae, and 2.9 times for E. faecalis. Significant antibiofilm activity of Urolife-Next was also noted. The severity of biofilm formation, which was assessed by changes in the optical density of cultures, decreased by 1.3–2.2 times, depending on the type of uropathogens.

Conclusions. The results of the study prove the efficiency of the dietary supplement Urolife-Next for the prevention of recurrences in patients with UTI. Its components (D-mannose, cranberry extract, vitamins D and C, hyaluronic acid, probiotics) influence the main pathogenetic factors.

Full Text

Restricted Access

About the authors

M. N. Slesarevskaya

FGBOU VO Pavlov First Saint Petersburg State Medical University of the Ministry of Health of Russia

Author for correspondence.
Email: mns-1971@yandex.ru
ORCID iD: 0000-0002-4911-6018
SPIN-code: 9602-7775

Ph.D., senior researcher at Scientific and Research Center of Urology in Scientific and Research Institute for Surgery and Emergency Medicine

Russian Federation, Saint Petersburg

I. V. Kuzmin

FGBOU VO Pavlov First Saint Petersburg State Medical University of the Ministry of Health of Russia

Email: kuzminigor@mail.ru
ORCID iD: 0000-0002-7724-7832
SPIN-code: 2684-4070

Ph.D., MD, professor of the Department of Urology

Russian Federation, Saint Petersburg

L. A. Kraeva

St. Petersburg Pasteur Institute of Epidemiology and Microbiology; Military Medical Academy named after S.M. Kirov

Email: lykraeva@yandex.ru
ORCID iD: 0000-0002-9115-3250
SPIN-code: 4863-4001

Ph.D., MD, Head of the Laboratory of Medical Bacteriology, professor of the Department of Microbiology

Russian Federation, Saint Petersburg; Saint Petersburg

E. V. Smirnova

Center for Hygiene and Epidemiology in the City of St. Petersburg

Email: f3_baklab@78cge.ru

Head of the Bacteriological Laboratory

Russian Federation, Saint Petersburg

D. A. Lisitsa

St. Petersburg State Chemical and Pharmaceutical University»

Email: darya-23.12@mail.ru

student

Russian Federation, Saint Petersburg

References

  1. Öztürk R., Murt A. Epidemiology of urological infections: a global burden. World J Urol. 2020;38(11):2669–2679. doi: 10.1007/s00345-019-03071-4
  2. Рафальский В.В., Моисеева Е.М. Эпидемиология неосложненных внебольничных инфекций мочевыводящих путей в Российской Федерации. Вестник урологии. 2018;6(2):30–37 [Rafalsky V.V., Moiseeva E.M. Epidemiology of uncomplicated outpatient urinary tract infections in the Russian Federation. Urology Herald. 2018;6(2):30–37. (In Russian)]. doi: 10.21886/2308-6424-2018-6-2-30-37.
  3. Murray B.O., Flores C., Williams C., Flusberg D.A, Marr E.E. et al. Recurrent Urinary Tract Infection: A Mystery in Search of Better Model Systems. Front Cell Infect Microbiol. 2021;11:691210. doi: 10.3389/fcimb.2021.691210.
  4. Ибишев Х.С., Лаптева Т.О., Крахоткин Д.В., Рябенченко Н.Н. Роль папилломавирусной инфекции в развитии рецидивирующей инфекции нижних мочевыводящих путей. Урология. 2019; (5):136–139.[Ibishev Kh.S., Lapteva T.O., Krachotkin D.V., Ryabenchenko N.N. The role of viral infection in the development of recurrent lower urinary tract infections. Urologiia. 2019;(5):136–139 (In Russian)] doi: 10.18565/urology.2019.5.136–139.
  5. Finucane T.E. ‘Urinary Tract Infection’ and the Microbiome. Am J Med. 2017;130(3):e97–e98. doi: 10.1016/j.amjmed.2016.08.018.
  6. Ибишев Х.С., Гаджиева З.К., Мамедов В.К. Эффективность биологически активной добавки Уронекст при хроническом рецидивирующем бактериально-вирусном цистите с множествен-ной устойчивостью к антибактериальным препаратам // Урология 2022(2):90–94 [Ibishev Kh.S., Gadzhieva Z.K., Mamedov V.K. Efficacy of Uronext in chronic recurrent bacterialviral cystitis with multiple resistance to antibacterial drugs. Urologiia 2022(2):90–94 (In Russian)]. doi: 10.18565/urology.2022.2.90-94.
  7. Слесаревская М.Н., Игнашов Ю.А., Кузьмин И.В., Аль-Шукри С.Х. Стойкая дизурия у женщин: этиологическая диагностика и лечение. Урологические ведомости. 2021;11(3):195–204. [Slesarevskaya M.N., Ignashov Y.A., Kuzmin I.V., Al-Shukri S.K. Persistent dysuria in women: etiological diagnostics and treatment. Urology reports (St.-Petersburg), 2021;11 (3):195–204 (In Russian)]. doi: 10.17816/uroved81948.
  8. Tomas M.E., Getman D., Donskey C.J., Hecker M.T. Overdiagnosis of Urinary Tract Infection and Underdiagnosis of Sexually Transmitted Infection in Adult Women Presenting to an Emergency Department. J Clin Microbiol. 2015;53(8):2686–2692. doi: 10.1128/JCM. 00670-15.
  9. Перепанова Т.С., Козлов Р.С., Руднов В.А., Синякова Л.А., Палагин И.С. Антимикробная терапия и профилактика инфекций почек, мочевыводящих путей и мужских половых органов. Федеральные клинические рекомендации. М., 2022. 126 с. [Perepanova T.S., Koz-lov R.S., Rudnov V.A., Sinjakova L.A., Palagin I.S. Antimicrobial therapy and prevention of kidney, urinary tract and male genital infections. Federal clinical guidelines. Moscow. 2022; 126 p. (In Russian)]
  10. Bonkat G., Bartoletti R., Bruyère F., Cai T., Geerlings S.E. et al. EAU Guidelines on Urological Infections. European Association of Urology, 2023. Досутпно по ссылке: https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Urological-infections-2023.pdf
  11. Шорманов И.С., Соловьев А.С., Чирков И.А., Щедров Д.Н., Красняк С.С., Шадеркин И.А. Возможности препаратов на основе D-маннозы и растительных компонентов в лечении и профилактике рецидивирующих инфекций нижних мочевых путей у женщин. Урологические ведомости. 2022;12(1): 13-20 [Shormanov I.S., Solo-vyov A.S., Chirkov I.A., Shchedrov D.N., Krasnyak S.S., Shaderkin I.A. Opportunities of drugs based on D-mannose and herbal components in the treatment and prevention of recurrent lower urinary tract infections in women. Urology reports (St.-Petersburg). 2022;12(1):13–20 (In Russian)]. doi: 10.17816/uroved84084.
  12. Слесаревская М.Н., Кузьмин И.В., Аль-Шукри С.Х. Инфекция нижних мочевыводящих путей: новые возможности фитотерапии. Урология 2022;(2):103–112 [Slesarevskaya M.N., Kuz’min I.V., Al-Shukri S.H. Infection of the lower urinary tract: new possibilities of herbal medicine. Urologiia. 2022;(2):103–112 (In Russian)]. doi: 10.18565/urology.2022.2.103-112.
  13. Кульчавеня Е.В., Неймарк А.И., Цуканов А.Ю., Плугин П.С., Неймарк А.Б., Раздорская М.В. Комбинированная терапия больных рецидивирующим циститом с применением комплекса природных антимикробных пептидов и цитокинов: первые результаты. Урология. 2022;(6):47–55 [Kulchavenya E.V., Neymark A.I., Tcuka-nov A.Yu., Plugin P.S., Neymark A.B., Razdorskaya M.V. Combined therapy of patients with recurrent cystitis using a complex of natural antimicrobial peptides and cytokines: first results. Urologiia 2022;(6):47–55 (In Russian)]. doi: 10.18565/urology.2022.6.47-55
  14. Алиджанов Ж.Ф., Абдуфаттаев У.А., Махмудов А.Т., Мирхами-дов Д.Х., Хаджиханов Ф.А., Агзамов А.В. и др. Разработка и клиническое испытание русскоязычной версии шкалы оценки симптомов острого цистита – ACSS // Урология. 2014. №6. С.14–22 [Alidjanov J.F., Abdufattaev U.A., Makhmudov A.T., Mirkhamidov D.Kh., Khadzhikhanov F.A., Agzamov A.V. Development and clinical testing of the russian version of the acute cystitis symptom score ‒ ACSS. Urologiia. 2014;(6):14–22 (In Russian)]
  15. Определение чувствительности микроорганизмов к антимикробным препаратам. Версия 2021-01. Рекомендации Межрегиональной ассоциации по клинической микробиологии и антимикробной химиотерапии МАКМАХ;222 c. URL: https://www.antibiotic.ru/files/321/clrec-dsma2021.pdf (дата обращения 18.12.2023). [Determination of the sensitivity of microorganisms to antimicrobial drugs. Version 2021-01. Recommendations of the Interregional аssociation for clinical microbiology and antimicrobial chemotherapy AKMAKH;222 p. [Electronic resource]. URL: https://www.antibiotic.ru/files/321/clrec-dsma2021.pdf (accessed 18.12.2023). (In Russian)].
  16. The European Committee on Antimicrobial Susceptibility Testing. Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST. Version 13.0, 2023. http://www.eucast.org. Доступно по ссылке https://www.treata.academy/wp-content/uploads/2023/07/Eucast-2023.pdf
  17. Благонравова А.С., Афонин А.Н., Воробьева О.Н., Широкова И.Ю. Сравнительный анализ адгезивности микроорганизмов, выделен- ных от больных и с объектов внешней среды лечебно-профилактических учреждений. Медицинский альманах 2011;5(18):215–218 [Blagonravova A.S., Afonin A.N., Vorobeva O.N., Shirokova I.Yu. Comparative analysis of the adhesiveness of microorganisms isolated from patients and from objects of the external environment of medical institutions. Meditsinskiy almanah = Medical Almanac 2011;5(18):215–218 (In Russian)].
  18. De Nunzio C., Bartoletti R., Tubaro A., Simonato A., Ficarra V.. Role of D-Mannose in the Prevention of Recurrent Uncomplicated Cystitis: State of the Art and Future Perspectives. Antibiotics (Basel). 2021;10(4):373. doi: 10.3390/antibiotics10040373.
  19. Hatton N.E., Baumann C.G., Fascione M.A. Developments in Mannose-Based Treatments for Uropathogenic Escherichia coli-Induced Urinary Tract Infections. Chembiochem. 2021;22(4):613–629. doi: 10.1002/cbic.202000406.
  20. Porru D., Parmigiani A., Tinelli C., Barletta D., Choussos D., Di Franco C. et al. Oral D-mannose in recurrent urinary tract infections in women: a pilot study. J ClinUrol. 2014;7(3):208–213.doi: 10.1177/2051415813518332.
  21. Кузьмин И.В., Слесаревская М.Н., Аль-Шукри С.Х. D-манноза в профилактике и лечении инфекций нижних мочевыводящих путей: патогенетические основы и клинические результаты. Урология. 2020;(4):131–138. [Kuz’min I.V., Slesarevskaya M.N., Al-Shukri S.H. D-mannose for prevention and treatment of lower urinary tract infection: pathogenetic basics and clinical results. Urologiia. 2020;(4):131–138 (In Russian)]. doi: 10.18565/urology.2020. 4.131–138.
  22. Кузьмин И.В., Слесаревская М.Н., Аль-Шукри С.Х. Антиадгезивная стратегия неантибактериальной профилатики рецидивирующей инфекции нижних мочевыводящих путей. Урология. 2021;(3):5–12 [Kuz’min I.V., Slesarevskaya M.N., Al-Shukri S.H. Antiadhesive strategy for non-antibacterial prophylaxis of recurrent lower urinary tract infections. Urologiia. 2021;(3):5–12 (In Russian)]. doi: 10.18565/urology.2021.3:5–12.
  23. Zafriri D., Ofek I., Adar R., Pocino M., Sharon N. Inhibitory activity of cranberry juice on adherence of type 1 and type P fimbriated Escherichia coli to eucaryotic cells. Antimicrob Agents Chemother. 1989;33(1):92–98. doi: 10.1128/AAC.33.1.92.
  24. Howell A.B., Vorsa N., Der Marderosian A., Foo L. Y. Inhibition of the adherence of P-fimbriated Escherichia coli to uroepithelial-cell surfaces by proanthocyanidin extracts from cranberries. N Engl J Med. 1998;339(15):1085–1086. doi: 10.1056/NEJM199810083391516.
  25. Liu Y., Black M.A., Caron L., Camesano T.A. Role of cranberry juice on molecular-scale surface characteristics and adhesion behavior of Escherichia coli. Biotechnol Bioeng. 2006;93(2):297–305. doi: 10.1002/bit.20675.
  26. Hisano M., Bruschini H., Nicodemo A.C., Srougi M. Cranberries and lower urinary tract infection prevention. Clinics (Sao Paulo). 2012;67(6):661–668. doi: 10.6061/clinics/2012(06)18.
  27. Tabasi M., Asadi Karam M.R., Habibi M., Yekaninejad M.S,. Bouzari S. Phenotypic Assays to Determine Virulence Factors of Uropathogenic Escherichia coli (UPEC) Isolates and their Correlation with Antibiotic Resistance Pattern. Osong Public Health Res Perspect. 2015;6(4):261–268. doi: 10.1016/j.phrp.2015.08.002.
  28. Reid G., Bruce A.W. Probiotics to prevent urinary tract infections: the rationale and evidence. World J Urol. 2006;24(1):28–32. doi: 10.1007/s00345-005-0043-1.
  29. Fazly Bazzaz B.S., Darvishi Fork S., Ahmadi R,, Khameneh B. Deep insights into urinary tract infections and effective natural remedies. Afr J Urol.2021;27:6. Doi: /10.1186/s12301-020-00111-z.
  30. Aroutcheva A., Gariti D., Simon M., Shott S., Faro J., Simoes J.A., Gurguis A., Faro S. Defense factors of vaginal lactobacilli. Am J Obstet Gynecol. 2001;185(2):375–379. doi: 10.1067/mob.2001.115867.
  31. Hassuna N.A., Rabie E.M., Mahd W.K.M., Refaie M.M.M, Yousef R.K.M., Abdelraheem W.M. Antibacterial effect of vitamin C against uropathogenic E. coli in vitro and in vivo. BMC Microbiol. 2023;23(1):112. doi: 10.1186/s12866-023-02856-3.
  32. Захарова И.Н., Цуцаева А.Н., Долбня С.В., Курьянинова В.А., Климов Л.Я. и др. Инфекции мочевых путей и витамин D: перспективы использования в профилактике и лечении. Медицинский совет. 2021;(11):148–155 [Zakharova I.N., Tsutsaeva A.N., Dolbnya S.V., Kuryaninova V.A., Klimov L.Ya.,et al. Urinary tract infections and vitamin D: prospects for use in prevention and treatment. Meditsinskiy sovet = Medical Council. 2021;(11):148–155. (In Russian.)]. doi: 10.21518/2079-701X-2021-11-148-155.
  33. Golpour A., Bereswill S., Heimesaat M.M. Antimicrobial and Immune-Modulatory Effects of Vitamin D Provide Promising Antibiotics-Independent Approaches to Tackle Bacterial Infections - Lessons Learnt from a Literature Survey. Eur J Microbiol Immunol (Bp). 2019;9(3):80–87. doi: 10.1556/1886.2019.00014.
  34. Gupta R.C., Lall R., Srivastava A., Sinha A. Hyaluronic Acid: Molecular Mechanisms and Therapeutic Trajectory. Front Vet Sci. 2019;6:192. doi: 10.3389/fvets.2019.00192.
  35. Goddard J.C., Janssen D.A.W. Intravesical hyaluronic acid and chondroitin sulfate for recurrent urinary tract infections: systematic review and meta-analysis. Int Urogynecol J. 2018;29(7):933–942. doi: 10.1007/s00192-017-3508-z.
  36. Schiavi M.C., Porpora M.G., Vena F., Prata G., Sciuga V., et al. Orally Administered Combination of Hyaluronic Acid, Chondroitin Sulfate, Curcumin, and Quercetin in the Prevention of Postcoital Recurrent Urinary Tract Infections: Analysis of 98 Women in Reproductive Age After 6 Months of Treatment. Female Pelvic Med Reconstr Surg. 2019;25(4):309–312. doi: 10.1097/SPV.0000000000000560.
  37. Crocetto F., Balsamo R., Amicuzi U., De Luca L., Falcone A., et al. Novel Key Ingredients in Urinary Tract Health-The Role of D-mannose, Chondroitin Sulphate, Hyaluronic Acid, and N-acetylcysteine in Urinary Tract Infections (Uroial PLUS®). Nutrients. 2023;15(16):3573. doi: 10.3390/nu15163573.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Figure. Evaluation of the antibacterial effect of Urolife-Next dietary supplement against Escherichia coli (MIC 100 mg/ml)

Download (141KB)
Indexing metadata

Copyright (c) 2024 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies